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Abstract
Background: Rhabdomyosarcoma (RMS), which can be classified as embryonal RMS (ERMS) and alveolar RMS
(ARMS), represents the most frequent soft tissue sarcoma in the pediatric population; the latter shows greater
aggressiveness and metastatic potential with respect to the former. Epigenetic alterations in cancer include DNA
methylation changes and histone modifications that influence overall gene expression patterns. Different tumor
subtypes are characterized by distinct methylation signatures that could facilitate early disease detection and
greater prognostic accuracy.
Methods: A genome-wide approach was used to examine methylation patterns associated with different
prognoses, and DNA methylome analysis was carried out using the Agilent Human DNA Methylation platform. The
results were validated using bisulfite sequencing and 5-aza-2′deoxycytidine treatment in RMS cell lines. Some in
vitro functional studies were also performed to explore the involvement of a target gene in RMS tumor cells.
Results: In accordance with the Intergroup Rhabdomyosarcoma Study (IRS) grouping, study results showed that
distinct methylation patterns distinguish RMS subgroups and that a cluster of protocadherin genes are
hypermethylated in metastatic RMS. Among these, PCDHA4, whose expression was decreased by DNA methylation,
emerged as a down-regulated gene in the metastatic samples. As PCDHA4-silenced cells have a significantly higher
cell proliferation rate paralleled by higher cell invasiveness, PCDHA4 seems to behave as a tumor suppressor in
metastatic RMS.
Conclusion: Study results demonstrated that DNA methylation patterns distinguish between metastatic and non-
metastatic RMS and suggest that epigenetic regulation of specific genes could represent a novel therapeutic target
that could enhance the efficiency of RMS treatments.
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Background
Rhabdomyosarcoma (RMS) represents the most frequent
soft tissue sarcoma in pediatric patients. The two main
histological subtypes of RMS tumors, alveolar RMS
(ARMS) and embryonal RMS (ERMS), have distinct
molecular and clinical profiles. The former, in fact, is char-
acterized by more aggressive behavior and a higher ten-
dency to present with signs of metastatic disease at
diagnosis and to relapse after treatment [1]. Approxi-
mately 80 % of ARMS harbor the reciprocal chromosomal
translocation t(2;13) (q35;q14) or the less common variant
translocation t(1;13)(p36;q14) in which PAX3 and FOXO1,
or PAX7 and FOXO1 genes, respectively, are juxtaposed
[2]. The latter subtype, instead, is not characterized by
specific genetic aberrations except for a loss of heterozy-
gosity at 11p15, which could mean that this region
contains tumor suppressor genes.
Over the past decade many genome-wide studies
have demonstrated that fusion-positive and negative
RMS present different gene expression signatures [3,
4]. Despite the low rate of gene mutations shown by
RMS, recent genomic studies have revealed that re-
current mutations in several key genes characterize
different RMS subtypes. In particular, mutations in
receptor tyrosine kinase/RAS/PIK3CA and FGFR
signaling predominately affect fusion negative tumors
[5]. The presence of metastasis at diagnosis repre-
sents the strongest predictor of poor outcome, and
the 5-year survival rate for patients with metastatic
disease is approximately 30 % [6].
The characterization of specific de-regulated genes in
metastatic samples may help to define the tumor’s meta-
static potential at a molecular level and to monitor disease
progression as well as its response to therapy. Growing
evidence indicates that normal DNA methylation patterns
are altered in cancer cells as there is an overall decrease in
the genomic content in 5-methylcytosine and frequent
hypermethylation and inactivation of tumor suppressor
genes [7]. Aberrant DNA methylation in candidate genes
such as FGFR1 [8], JUP [9], MYOD1 [10], PAX3 [11],
RASSF1 [12], BMP2 [13] and CAV1 [14] has also been
described in RMS.
Microarray and novel sequencing techniques have fa-
cilitated the comprehensive analysis of the genome and
have paved the way for genome-wide scanning of DNA
methylation states [15]. Epigenetic information such as
DNA methylation profiling could, in fact, help to identify
tumor subtypes and lead to more accurate diagnoses
[16–18]. Several genome-wide studies, which have dem-
onstrated that distinct methylation patterns are found in
ARMS vs ERMS and fusion-positive vs fusion-negative
tumors [19–21], have shown that PTEN and EMILIN1
are differentially expressed genes that may be regu-
lated by DNA methylation.
The current study aimed to examine methylation pat-
terns in alveolar and embryonal samples and to explore
epigenetic changes in different RMS subtypes at various
clinical stages. We delineated, for the first time, the associ-
ation between metastatic phenotype and DNA methyla-
tion pattern. Study results also uncovered a novel gene
whose expression is lowered by DNA methylation,
suggesting that epigenetic therapy could be utilized to im-
prove current treatment protocols of rhabdomyosarcoma.
Methods
Cell culture
Human ARMS (RH4 and RH30) and human ERMS cells
(RD and RH36) were maintained in Dulbecco’s modified
Eagle’s medium containing 10 % fetal calf serum, penicil-
lin (100 U/mL), and streptomycin (100 ug/mL) (Life
Technologies, Carlsbad, CA) at 37 °C in 5 % CO2 in a
humidified incubator. RH30 and RD cells were obtained
from American Type Culture Collection (Manassas, VA);
RH4 were gift from Prof. Pier Luigi Lollini (Dept. Medi-
cina Specialistica, Diagnostica e Sperimentale, University
of Bologna, Italy) [22]. RH36 were obtained from Dr.
Maria Tsokos (National Cancer Institute, Bethesda, MD)
[23]. A summary of RMS cell line features is available in
Additional file 1.
Tumor samples and ethics approval
Specimens were obtained from the Italian Association of
Pediatric Hematology and Oncology Soft Tissue Sarcoma
Bank at the Department of Women’s and Children’s
Health, University of Padova (Padova, Italy). The study,
part of a clinical trial carried out in association with the
Association Italiana Ematologia Pediatrica AIEOP (Italian
Association of Pediatric Hematology and Oncology), was
approved by the local ethics committee. Selected clinical
parameters of RMS patients used in the analysis are avail-
able in the Additional file 2.
Total RNA and DNA isolation
Genomic DNA was isolated from RMS cell lines and from
RMS tumor biopsies using Trizol® Reagent (Life Tech-
nologies) after RNA extraction following the manufac-
turer’s instructions. The commercially available Qiamp
DNA mini Kit (Qiagen) was used to purify the DNA.
Total DNA was quantified using the ND-1000 spectro-
photometer (Nanodrop, Wilmington, DE).
Genome-wide DNA methylation profiles
Four μg of genomic DNA was fragmented by sonication
and purified using Mini-Elute columns (Qiagen Co.,
Hilden Germany), and the amount of double-stranded
DNA (dsDNA) was measured using the Qubit instru-
ment (Invitrogen, Life Technologies Co., Carlsbad, CA,
USA). The success of fragmentation was evaluated using
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the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA). The MethylMiner Methylated DNA en-
richment kit (Invitrogen, Life Technologies Co., Carlsbad,
CA, USA) was used to enrich the fraction of methylated
dsDNA, starting from 2 μg of fragmented whole genomic
DNA. Ten ng of methylated dsDNA for each sample was
amplified using Whole Genome Amplification (WGA,
Sigma-Aldrich Co., St. Louis, MO, USA). Genomic DNA
was used as the control for each sample. DNA methyla-
tion profiling was carried out in RMS tumor samples
using the Human DNA Methylation Microarray (Agilent
Technologies, Santa Clara, CA, USA) consisting of about
244,000 (60-mer) probes designed to interrogate about
27,000 known CpG islands. The control genomic DNA
and methylated dsDNA were labeled with Cy3 and
Cy5 dye respectively using Agilent Genomic DNA la-
beling kit PLUS (Agilent Technologies, Santa Clara,
CA, USA) and competitively hybridized to Human
DNA Methylation microarrays platforms (GEO ID:
GPL10878). The hybridization was carried out at 67 °C for
40 h in a hybridization oven rotator (Agilent Technolo-
gies, Santa Clara, CA, USA). The arrays were washed with
Agilent ChiP-on-chip wash buffers as suggested by the
supplier. Slides were scanned on an Agilent microarray
scanner (model G2565CA), and Agilent Feature Extrac-
tion software version 10.7.3.1 was used for image analysis.
Availability of data and materials
Raw data are available on the GEO website using acces-
sion number GSE67201, and processed data are pre-
sented as Additional files 1, 2 and 3.
Statistical analysis of DNA methylation data
Intra-array normalization of methylation levels was
performed with linear and lowess normalization. Inter-
array normalization was performed with quantile
normalization [24] in order to correct experimental
distortions. The normalization function was applied to
the methylation data of all the experiments. Feature
Extraction Software (Agilent Technologies, Santa Clara,
CA, USA) provided spot quality measures with regard to
methylation expression data in order to evaluate the
quality and the liability of the hybridization data. In
particular, flag “glsFound” and “rlsFound” (set to 1 if the
spot had an intensity value that was significantly differ-
ent from the local background or to 0 in any other
cases) were used to filter out unreliable probes: flag
equal to 0 was to be noted as “not available (NA)”.
Probes with a high proportion of NA values (more than
25 %) were removed from the dataset to ensure more
robust, unbiased statistical analyses. When twenty-five
percent of NA was used as the threshold in the filtering
process, a total of 90.591 probes were obtained. The
microarray data were analyzed using the iChip R
bioconductor Package. The microarray data were proc-
essed in accordance with the instructions contained in
the package vignette (www.bioconductor.org/packages/
release/bioc/vignettes/iChip/inst/doc/iChip.pdf ).
Briefly, after normalization we computed the enrich-
ment measure using the lmtstat function (a wrapper
function of the empirical Bayes t-statistic from limma
package) provided by iChip package. Specifically, we
used the iChip2 function that implements the high
order hidden Ising model described in [25]. The iChip2
function was called with b = 1 following the specifica-
tions for low resolution arrays, while the other parame-
ters were left at the default value. iChip2 function
Enriched regions were called using an FRD cutoff of 0.2
and maxGap = 500 bp.
The genes associated to DMRs identified using iChip al-
gorithm were functionally analyzed using Gene Ontology
(GO) implemented by the Database for Annotation,
Visualization and Integrated Discovery (DAVID) tool [26].
The significantly enriched biological categories were iden-
tified using a Modified Fisher Exact p-value < 0.05.
Trichostatin A and 5-aza-2′-deoxycytidine treatments
RMS cells (0.25x106 cells/mL) grown in 100 mm dishes
were treated with demethylating agent 5-aza-2′- deoxycy-
tidine (5-Aza-dC) (Selleck Chemicals, Houston; TX,
USA), with TSA (Selleck Chemicals, Houston; TX, USA),
or with a combinatorial treatment using both agents. Con-
centrations varying from 100nM to 2 μM of 5-Aza-dC for
72 h and 200 ng/ml of TSA for 16 h were used. Cells were
harvested and processed for RNA or DNA extraction.
qRT-PCR for mRNA detection
For mRNA detection, 1 μg of total RNA was retrotran-
scribed with Superscript II (Life Technologies), and
qRT-PCRs were carried out with gene-specific primers
and the SYBR PCR Master Mix (Applied Biosystem, Life
Technologies) using a ViiA 7 Real-Time PCR System.
GADPH was selected for the endogenous normalization
of the gene expression analysis. The relative expression
levels between samples were calculated using the compara-
tive delta Ct (threshold cycle number) method (2-ΔΔCt) [27]
implemented in the ViiA 7 Real-Time PCR System soft-
ware. A 95 % confidence interval (IC) was calculated.
The relative expressions of non-clustered protocadher-
ins (PCDHs) were simultaneously analyzed using the
relative expression software tool (REST) which is able to
identify significance differences between two groups of
samples using a randomization test [28]. Permutation or
randomisation tests are useful alternatives to more
standard parametric tests because despite the fact that
they remain as powerful as more standard tests, they
make no distributional assumptions about the data. The
randomisation test repeatedly and randomly reallocates
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the observed values to the two groups and notes the
apparent effect (expression ratio in our case) each time.
A proportion of these effects, which are as great as those
actually observed in the experiment, gives the P-value of
the test.
The statistical analysis of PCDHA4 expression levels,
evaluated in an expanded cohort of samples, was per-
formed using Prism6 software, and the Mann–Whitney
U-test was used.
Sodium bisulfite treatment of DNA and bisulfite sequencing
One μg of genomic DNA was subjected to conversion
with sodium bisulfite using EZ DNA Methylation-Gold ™
kit (Zymo Research, Orange, CA, USA), following the
manufacturer’s instructions. One hundred ng of bisulfite-
converted DNA was used as template for the amplification
of candidate regions. Polymerase chain reaction (PCR)
was performed using methylation-independent primers
designed with the free online tool MethPrimer (http:/ita
sa.ucsf.edu/~urolab/methprimer;). The PCR products
were purified using the QIAquick PCR purification kit
(Qiagen Co., Hilden Germany) and subcloned into pSC-
A-amp/kan vector using the StrataClone PCR Cloning Kit
(Agilent Technologies, Santa Clara, CA, USA). Competent
cells were transformed with ligation reaction product and
grown in Luria Bertani (LB) agar plates supplemented
with 40 μg/ml of X-Gal (Promega Co., Madison, WI,
USA) and 50 μg/ml of ampicillin for 16 h at 37 °C. Blue-
white screening permitted identification of recombinant
bacteria. Selected clones were evaluated by colony PCR
performed using M13R and T7 universal primers (Invitro-
gen, Life Technologies Co., Carlsbad, CA, USA). The PCR
products were checked for the presence of inserts using
agarose electrophoresis, and those corresponding to
positive clones were purified using a QIAquick PCR
purification kit (Qiagen Co., Hilden Germany) and then
sequenced by 3500 Dx Genetic Analyzer sequencer
(Applied Biosystems, Life Technologies Co., Carlsbad, CA,
USA) using BigDye® Terminator v3.1 CycleSequencing Kit
(Applied Biosystems, Life Technologies Co., Carlsbad, CA,
USA) following the manufacturer’s instructions.
RNA interference
RH36 cells at 50 % to 70 % confluence were transfected
with small-interfering RNA (siRNA) for target gene
PCDHA4 (siPCDHA4) or with non-targeting siRNA
(siCONTROL) using Lipofectamine2000 transfection
reagent (Thermofisher Scientific). We performed prelim-
inary experiments in the attempt to achieve the highest
efficiency and reproducibility. The efficacy of gene
knockdown was evaluated at the mRNA level using
qRT-PCR analysis after 48 h of transfection.
Flow cytometric analysis of the cell cycle
After transfection, PCDHA4 silenced cells (siPCDHA4)
and control cells (siCONTROL) were harvested. For each
sample, 1x106 cells were fixed with 70 % cold ethanol,
washed in PBS, and incubated with propidium iodide
(50 μg/mL) and RNase (100 μg/mL) for 60 min at 37 °C.
Samples were run in a BD FACScan (Becton Dickinson,
Labware, Bedford, MA); the data were analyzed with
ModFitLT V3.0 software (Verity Software House, Top-
sham, ME). Two independent experiments were per-
formed with three replicates for each. A 95 % Confidence
interval (CI) was calculated.
Invasion Transwell Assay
Chemoinvasion was measured using 24- well BioCoat
Matrigel invasion chambers (Becton Dickinson) with an
8-μm pore polycarbonate filter coated with Matrigel.
The lower compartment contained 0.5 mL of 1 % serum
medium conditioned by the NIH3T3 cell line as a
chemoattractant or serum-free Dulbecco’s modified
Eagle’s medium as a control. In the upper compartment,
1x104 RH36 cells per well were placed in triplicate wells
and incubated for 18 h at 37 °C in a humidified incubator
with a 5%CO2 atmosphere. After incubation, the cells on
the filter’s upper surface were wiped off with a cotton
swab; the cells on the lower surface were, instead, fixed in
2.5 % glutaraldehyde, stained with 0.2 % crystal violet in
20 % methanol, and then photographed using a stereo-
microscope (model MZ16; Leica Microsystems) equipped
with a charge-coupled device (CCD) camera. Images were
processed using Corel-Draw software (Corel, Ottawa,
Canada), and the area occupied by the migrated cells was
measured using ImageJ software (http://rsbweb.nih.gov/ij,
last accessed September 4, 2009). A 95 % Confidence
interval (CI) was calculated.
Results
DNA methylation profiling in RMS tumor biopsies
We analyzed the DNA methylation profiles of 15 RMS
samples - 6 PAX3/FOXO1 positive ARMS, 3 PAX3/FOXO1
negative ARMS and 6 ERMS - using the Human DNA
methylation platform (Agilent) which is a collection of
244 k probes designed to interrogate about 27,000 known
human CpG islands. We compared the methylation pro-
files of PAX3/FOXO1 positive and negative RMS using the
iChip R Bioconductor Package [25]. Analysis of the data
(false discovery rate (FDR) <0.2) revealed that a set of
differentially methylated regions (DMRs) were able to
discriminate between the fusion positive and fusion nega-
tive RMS, as was previously demonstrated by Sun et al.
[21] (Additional file 3).
We then used iChip R Bioconductor Package to com-
pare the samples of disseminated and localized RMS
and identified 1394 regions differentially methylated
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(FDR < 0.2) able to discriminate metastatic vs non-
metastatic RMS (Additional file 3). We noted that the
majority of DMRs (86.5 %) showed a positive enrich-
ment value in the metastatic samples with respect that
in the non-metastatic ones highlighting those genes’
tendency for hypermethylation in samples with meta-
static disease. We then mapped the DMRs to the gen-
ome using the UCSC Genome browser and found that
only 357 DMRs localize in promoter regions (defined
as regions located from -2Kb + to 1 kb to transcription
start site, TSS) while all the other DMRs mapped in
intragenic regions or in CpG regions distal to known
coding sequences (intergenic regions).
Detection of novel methylated target genes in metastatic
and non-metastatic samples
To detect genes directly or indirectly modulated by DNA
methylation, we analyzed the genes associated to DMRs
with the DAVID functional annotation tool which per-
forms a GO-term analysis and identifies which functional
categories are over-represented. The terms analyzed have
a FDR-adjusted P value <0.05. We found a consistent
number of genes involved in cell adhesion (45 genes, P =
6,7E10−31), cell-cell signaling (18 genes, P = 2.3E-02) and
regulation of transcription (65 genes, P =4.8E10−4) which
were the three major significantly enriched functional cat-
egories (Table 1). Interestingly, we found many members
of the protocadherin clusters α,β,γ (PCDHs) in the cell ad-
hesion category (Fig. 1). We also observed that all DMRs
linked to protocadherins mapped in promoter regions.
The finding was interesting given that several studies have
demonstrated that some protocadherins play a tumor
suppressor role in many cancer types [29].
The terms of enriched classes referred to biological
processes identified by Gene Ontology (GO) classifica-
tion performed using the DAVID web tool. FDR, false
discovery rate. *Modified Fisher exact P-value identified
by DAVID.
Expression levels of protocadherins in RMS cell lines and
tumor biopsies
To study the involvement of protocadherins in RMS, we
tested the gene expression of some members of PCDH
α,β,γ clusters by qRT-PCR in both RMS cell lines and
tumor biopsies. The expression data were analyzed using
the relative expression software tool (REST) [28] which
makes it possible to identify genes whose expression is
different in two sample groups by applying a randomisa-
tion test. We analyzed 4 RMS cell lines, representative
of the two major subtypes of RMS: alveolar PAX3/
FOXO1 positive RMS cells (RH4, RH30) and embryonal
RMS cells (RD, RH36). We found significantly different
expressions for PCDHA12 (P = 0.021) and PCDHA4 (P
< 0.001) in the ARMS and ERMS cell lines (Fig. 2a), and
we found statistically significant different expression
levels of PCDHA4 (P = 0.030) and PCDHB7 (P = 0.004)
in the metastatic tumor samples (IV stage) with respect
to the non-metastatic ones (I-II-III stage) (Fig. 2b). Al-
though several protocadherins resulted differentially
expressed in the metastatic and non-metastatic RMS,
only PCDHA4 showed an opposite correlation between
methylation status and gene expression. We then evalu-
ated PCDHA4 expression in a larger cohort of RMS
samples (n = 61) and found that PCDHA4 levels are
higher in non-metastatic RMS (clinical stage I-II-III)
with respect to metastatic at diagnosis RMS samples
(IRS IV) (p < 0.05, Fig. 2c). A comparison of non-
metastatic and metastatic ARMS provided further con-
firmation of the association between PCDHA4 expres-
sion and clinical stage (p < 0.05, Fig. 2d).
Restoration of PCDHA4 expression in RMS cells treated
with 5Aza dC and trichostatin A
The evaluation of PCDHA4 expression levels in RMS
cell lines by qRT-PCR revealed different expression pat-
terns in ARMS (RH4 and RH30) and ERMS cell lines
(RD and RH36) (Fig. 3a). In order to analyze whether
DNA methylation can affect the gene expression in
alveolar and embryonal RMS, we treated RMS cell lines
with the demethylating agent 5-Aza-2′-deoxycytidine (5-
Aza-dC) either separately or in conjunction with the his-
tone deacetylase inhibitor Trichostatin A (TSA). It is
known that histone acetylation/deacetylation is a central
mechanism for regulating transcription through chroma-
tin remodeling. Indeed, many studies have suggested
that epigenetic cross-talk between DNA methylation and
histone acetylation is involved in gene transcription and
aberrant gene silencing in tumors. When we assessed
PCDHA4 expression level by qRT-PCR 72 h after treat-
ment of increasing doses of 5-Aza-dC we did not
Table 1 Summary and functional annotation of methylated genes over-represented in metastatic vs non-metastatic RMS samples
Biological Process ID Terms Count p-value* FDR
GO:0016337 cell-cell adhesion 45 6.70E-31 1.10E-27
GO:0007267 cell-cell-signalling 18 2.30E-02 3.2E + 01
GO:0006355 regulation of trancsription 65 4.80E-04 7.90E-01
GO:0048598 embryonic morphogenesis 16 1.90E-04 1.30E-02
GO:0022406 cell cycle phase 11 1.50E-01 9.30E + 01
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observe any change in ERMS cell lines (RD and RH36),
but we did notice a dose dependent restoration of
PCDHA4 expression in RH30, one of the ARMS cell
lines representing the metastatic tumor (p < 0.05, Fig. 3b).
Instead, while treatment with trichostatin A alone did
not lead to of the restoration of PCDHA4 expression,
the combination of 5Aza-dC and TSA synergistically
augmented mRNA expression of PCDHA4 in ARMS cell
lines RH30. Conversely, no effect on PCDHA4 expres-
sion was observed in ERMS cell lines after combined
treatments (Fig. 3c). Taken together, these results suggest
that epigenetic regulation of PCDHA4 may be present in
RMS cells, and they underline the synergic effect of the
two different drugs.
Bisulfite sequencing confirms that PCDHA4 promoter has
a different methylation pattern in RMS cell lines
To verify the promoter methylation status of PCDHA4,
we performed bisulfite Sanger sequencing in four RMS
cell lines. As above, we used two positive ARMS cell lines
(RH4 and RH30) and two ERMS cell lines (RD and
RH36). We designed a bisulfite sequencing assay inside
the CpG island that overlaps the promoter of PCDHA4
and also contains the DMR identified by microarray ex-
periments (Fig. 4). The bisulfite-converted DNA region
was amplified by PCR and subcloned into bacterial vector.
We then performed Sanger sequencing of at least eight
clones obtained by subcloning the amplified PCDHA4 pu-
tative promoter region. Bisulfite sequencing data showed
that the methylation level was higher in the ARMS
(72.94 % of 5′m-CpG in RH4 and 91.42 % of 5′m-CpG in
RH30) than in ERMS cell lines (41.75 % of 5′m-CpG in
RH36 and 44.53 % of 5′m-CpG in RD) (Fig. 4). We thus
confirmed that different methylation levels of PCDHA4
promoter regions characterize RMS cell lines originating
from metastatic and non-metastatic tumors.
PCDHA4 involvement in tumor growth of RMS cells
To evaluate the potential role of PCDHA4 as a tumor sup-
pressor in RMS, we transiently silenced PCDHA4 in
RH36, which is the ERMS cell line with the highest en-
dogenous expression level of this gene. Transient modula-
tion was evaluated 48 h post-transfection for expression
and for biological effects. We observed an approximate
70 % reduction in gene expression when we used a qRT-
PCR assay (Fig. 5a). Cell cycle progression of the trans-
fected cells was assayed by flow cytometry. An increase in
the proliferation rate as well as a G0/G1 phase decrease
were observed in the cells with low levels of PCDHA4
(siPCDHA4) with respect to what was noted in the
control cells (siCONTROL) (Fig. 5b). Moreover, when
invasion through Matrigel was evaluated by transwell as-
says, we noted enhanced mobility of PCDHA4 silenced
cells (siPCDHA4) with respect to that in controls (siCON-
TROL) (Fig. 5c). Taken together these preliminary results
suggest that PCDHA4 could play the role of a tumor
Fig. 1 A heatmap of DMRs associated to PCDHs genes. The
heatmap shows the DNA methylation patterns of protocadherin loci
(measured as log2 ratio of methylated dsDNA/ total genomic DNA)
for the RMS samples analyzed. Each column represents the profile of
a specific RMS sample, and each row represents the differentially
methylated regions (DMRs) associated to PCDHs genes identified
with iChip algorithm by comparing metastatic and non-metastatic
samples. The enrichment value, expressed as moderated t-statistics
extracted using the eBayes function, is associated to each DMR as
result of iChip analysis. A positive enrichment value indicates
hypermethylation in metastatic vs non-metastatic samples
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suppressor and may be involved in promoting cell cycle
progression and cell invasion of RMS cells.
Discussion
During the current study, methylation profiling of RMS
samples using a genome-wide approach uncovered
differences in DNA methylation signatures of metastatic
and localized RMS and highlighted that epigenetic alter-
ations are peculiar to disseminated RMS. The findings
demonstrated that DNA methylation can contribute to
defining the molecular features of RMS subgroups and
can thus increase the accuracy of RMS subtype classifi-
cation. PCDHA4 was identified as a gene whose expres-
sion was decreased in metastatic with respect to non-
Fig. 2 PCDHs genes expression level by qRT-PCR analysis. Relative expression levels of 15 PCDHs genes in PAX3/FOXO1 ARMS cell lines compared
to ERMS cell lines (a) and in metastatic RMS tumor samples compared to non-metastatic RMS tumor samples (n = 15) (b). Data distribution is
represented by box plot analysis performed using REST software. The relative expression of the PCDHA4 gene was evaluated in a larger cohort of
RMS samples (n = 61). c PCDHA4 mRNA levels were lower in metastatic RMS samples (stage IV) with respect to non-metastatic RMS (stage I-II-III).
d Comparison of metastatic ARMS vs non-metastatic ARMS confirmed the association of low PCDHA4 levels with the metastatic phenotype.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene for data normalization. Relative expression (RQ) was
calculated using ΔΔCt method. Statistical analysis (Mann–Whitney U-test) was performed using Prism 6 software. * P < 0.05; **P < 0.01; ***P < 0.001
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metastatic RMS. Preliminary data also suggested that
PCDHA4 may act as a tumor suppressor in RMS cells
and that it may be partially inactivated by DNA
methylation.
Several investigators including ourselves have exam-
ined the different behaviors and molecular features of
alveolar and embryonal RMS, and over the past decade
many studies have confirmed that gene expression pro-
files distinguish between alveolar PAX3/FOXO1 positive
ARMS and PAX3/FOXO1 negative ARMS and ERMS [3,
4]. Although the mechanisms underlying different gene
regulation patterns are still under investigation, it is
known that epigenetic modifications, and in particular
DNA methylation, can modulate gene expression and
represents a challenging area of cancer research. Recent
studies have demonstrated that DNA methylation pro-
files distinguish between RMS fusion-positive and nega-
tive samples and could be used to improve the
molecular classification of rhabdomyosarcoma [19, 21].
Analysis of our microarray data confirm that alveolar
PAX3/FOXO1 positive samples have a different methyla-
tion signature with respect to RMS fusion-negative ones.
It is important to remember that our analysis of DNA
methylation differences in metastatic and non-metastatic
tumors is based on the Intergroup Rhabdomyosarcoma
Study (IRS) grouping which is highly predictive of tumor
outcome. In particular, patients classified as IRS IV group,
which is characterized by metastatic disease, have long-
term failure-free survival (FFS) rates of <30 % [6, 30].
When we compared non-metastatic (IRS I-II-II) with
metastatic (IRS IV) RMS patients, we found quite distinct
methylation signatures. This data, together with those
produced by other genome-wide studies highlight methy-
lation pattern changes in different RMS subtypes and
seem to suggest that an epigenetic therapy could be
appropriate to treat rhabdomyosarcoma. Indeed, DNA
methylation is an excellent target for anti-cancer therapy
as it involves a reversible process that does not affect the
DNA sequence.
No epigenetic drugs are currently included in RMS
clinical protocols, but over the past few years, several
new anti-cancer drugs with epigenetic activities have
received approval for clinical trials on other solid can-
cers leading to a detailed characterization of their mech-
anisms of action. Some FDA-approved drugs for the
treatment of solid cancers are 5-Aza that target histone
deacetylase (HDAC) in metastatic non-small cell lung
cancer [31] and inhibitors of EZH2, a subunit of Poly-
comb repressive complex in diffuse large B cell Lymph-
oma (DLBCL) [32].
When we analyzed the distribution in the genome of the
differentially methylated regions (DMRs) identified by
microarray analysis, we found that only 25 % of them
overlap with promoter regions (regions defined as 2 kb
upstream and 1 kb downstream of RefSeq transcription
star site) while the others map inside gene bodies or are
localized in intergenic regions distal to known genes.
Advances in genome-wide approaches have demonstrated
Fig. 3 Relative expression of PCDHA4 in RMS cells after treatment
with 5-Aza-dC and/or TSA. The expression level of PCDHA4 was
evaluated in 4 RMS cell lines (a), in RMS cells after 72 h of treatment
with increasing doses of 5-aza-dC (100 nM, 250 nM, 500 nM, 1 uM
and 2 uM) (b) and in RMS cells after treatment with 1uM of 5-aza-dC
(72 h), 200 ng/mL of trichostatin A (16 h) or a combination of both
(c) by qRT-PCR. A housekeeping GAPDH gene was used as an
internal control for normalization, and DMSO-treated cells were
used as the calibrator. Relative expression was calculated using ΔΔCt
method. The error bar represents a 95 % confidence interval (IC).
RH30, RH4: PAX3/FOXO1 ARMS cell lines; RD, RH36: ERMS cell lines;
5-aza-dC: 5-aza-2′-deoxycytidine
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that methylation varies depending upon the specific gen-
omic context. Although the majority of studies have fo-
cused on methylation in the promoter region adjacent to
the transcription start site (TSS), methylation of the gene
body or intergenic regions seems to have a functional role
and contributes to defining the whole picture of the
methylation status [33].
Our microarray analysis revealed an abnormal methy-
lation pattern in promoters of protocadherins (PCDHs).
PCDHs, which are a group of transmembrane proteins,
constitute the largest subfamily of the cadherin cell-
adhesion molecules. In mammals, PCDHs are organized
in clusters (α,β,γ) or are scattered throughout the
genome [29, 34]. The methylation value [the enrichment
value expressed as moderated t-statistics computed
using the eBayes function (limma-t)] of DMRs associated
to protocadherins was that of a common hypermethyla-
tion level of promoter regions in metastatic compared to
non-metastatic samples. Using qRT-PCR assays, we ana-
lyzed the expression levels of some PCDHs and observed
that the correlation between promoter hypermethylation
and downregulation of genes is very low, indicating that
epigenetic alterations may have an alternative effect with
respect to typical gene regulation. Other genome wide
studies have reported the same result suggesting that the
correlation between DNA methylation and mRNA
expression does not always conform to the paradigmatic
inverse correlation between the two processes [21].
Our findings highlighted PCDHA4 as an example of a
gene in RMS whose expression differs in metastatic and
Fig. 4 Sanger bisulfite sequencing of PCDHA4 promoter region revealed different methylation patterns in PAX3/FOXO1 ARMS cell lines and ERMS
cells. Sequencing was performed for at least 8 clones obtained by subcloning bisulfite-converted promoter region. Sequenced region spanned from
position +94 to +828, where position +1 corresponds to the gene transcription start site (TSS). The sequence investigated maps on a predicted CpG
island and includes the region identified with iChip algorithm. ARMS cell lines have high methylation levels (RH4, RH30) with respect to ERMS cell lines
(RH36, RD). Circles: cytosine within CpG dinucleotides; black circles: methylated cytosine; white circles: unmethylated cytosine
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non-metastatic RMS samples. We hypothesize that the
decrease in PCDHA4 expression depended on DNA
methylation. Interestingly, a recent methylation profiling
study of cervical cancer samples revealed a methylation
silencing of many clustered protocadherins in the cancer
with respect to the control cells. The study also reported
that there was a positive correlation between methyla-
tion frequency of PCDHA4 and PCDHA13 and tumor
severity, highlighting the role of PCDHA4 silencing in
cancer progression [35]. Other studies have demon-
strated the involvement of several protocadherins in
tumor processes. It has been shown that protocadherins
behave as tumor suppressor genes in many solid cancers
such as non-small-cell lung cancer, gastric and prostate
cancer. It has also been demonstrated that their involve-
ment is due to aberrant DNA methylation that deter-
mines an altered expression pattern [36–38].
In the light of these findings, we performed some in
vitro functional studies on RMS cells. These preliminary
data uncovered the potential role of PCDHA4 as a tumor
suppressor in RMS. In fact, we observed that PCDHA4-si-
lenced cells acquire a more aggressive phenotype, as dem-
onstrated by the increase in proliferation rate and
invasiveness that was found. Further functional studies are
warranted to clarify the involvement of PCDHA4 in
rhabdomyosarcoma.
Treatment with 5-Aza-dC and/or TSA of RMS cell lines
suggested that there is epigenetic control of PCDHA4
expression. Although the restoration of PCDHA4 expres-
sion was noted only in one alveolar cell line (RH30), no
changes in PCDHA4 expression levels were observed in
embryonal cell lines (RD, RH36). Bisulfite sequencing thus
confirmed the different methylation status of the
PCDHA4 promoter region in alveolar and embryonal cell
lines. Taken together, these data suggest that DNA methy-
lation probably decreases the transcription of PCDHA4
selectively in a RMS subgroup. Our experiments also
demonstrated that a combination of 5-aza-2′-deoxycytine
and trichostatin A drugs in RMS cells act synergistically to
restore PCDHA4 expression confirming the potential
utility of a combination therapy. The combination of
demethylating molecules with drugs that target histone
modifications may enhance the efficacy of treatment as
already demonstrated by other studies [39, 40].
Conclusion
The current study has demonstrated for the first time
that DNA methylation patterns differ in metastatic and
non-metastatic RMS, and it has confirmed that epigen-
etic changes characterize rhabdomyosarcoma subtypes.
In vitro treatment of RMS cells with demethylating
agent 5-Aza-dC alone or together with histone deacety-
lase inhibitor suggests that there is epigenetic control of
the gene regulation of PCDHA4. These findings were
Fig. 5 PCDHA4 involvement in tumor cell growth and invasion.
RH36 cells that express high levels of PCDHA4 were transiently
transfected with siRNA for PCDHA4 (siPCDHA4) or negative siRNA
control (siCONTROL). The efficiency of silencing was evaluated using
qRT-PCR (a). Transfected cells were used to analyze cell cycle
distribution (b) or invasion c). The results are shown as mean ± IC of
the percentage (%) of proliferation, measured using flow
cytometry 48 h after transfection (b) and as the area covered
by Matrigel-invading cells (c). Cell proliferation and invasion of
PCDHA4 silenced cells are shown relative to control values
(siCONTROL). Two independent experiments were performed in
triplicate and mean results are shown. *P < 0.05; (The error bar
represent a 95 % confidence interval, IC)
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supported by bisulfite sequencing of PCDHA4 promoter
in RMS cells. Preliminary functional studies also suggested
that PCDHA4 could play a tumor suppressor role since it
was hypermethylated and silenced in alveolar RMS cell
lines representative of a metastatic tumor. Taken together,
the findings point to a potential biomarker and a possible
new therapeutic target for metastatic RMS.
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